Skip to main content

Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis)

  • Chapter
  • First Online:
Management of Soft Tissue Sarcoma

Abstract

Desmoids are enigmatic clonal malignancies of myofibroblastic cells that do not have the ability to metastasize, but cause morbidity and occasionally mortality by locally aggressive growth. They are sometimes termed deep fibromatoses, to distinguish them from superficial fibromatoses such as Dupuytren contracture, trigger finger, or Peyronie disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dumont AG, Rink L, Godwin AK, et al. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2012;23:1335–40.

    Article  CAS  PubMed  Google Scholar 

  3. Smith AJ, Lewis JJ, Merchant NB, et al. Surgical management of intra-abdominal desmoid tumours. Br J Surg. 2000;87:608–13.

    Article  CAS  PubMed  Google Scholar 

  4. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999;86:2045–52.

    Article  CAS  PubMed  Google Scholar 

  5. Sundaram M, Duffrin H, McGuire MH, et al. Synchronous multicentric desmoid tumors (aggressive fibromatosis) of the extremities. Skeletal Radiol. 1988;17:16–9.

    Article  CAS  PubMed  Google Scholar 

  6. Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging. 1988;6:237–48.

    Article  CAS  PubMed  Google Scholar 

  7. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davies DR, Armstrong JG, Thakker N, et al. Severe Gardner syndrome in families with mutations restricted to a specific region of the APC gene. Am J Hum Genet. 1995;57:1151–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995;4:337–40.

    Article  CAS  PubMed  Google Scholar 

  10. Domont J, Benard J, Lacroix L, et al. Detection of {beta}-catenin mutations in primary extra-abdominal fibromatosis (EAF): an ancillary diagnostic tool. J Clin Oncol. 2008;26:10518.

    PubMed  Google Scholar 

  11. Lazar AJ, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol. 2009;21:352–9.

    Article  CAS  PubMed  Google Scholar 

  12. Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54:606–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151:329–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509–14.

    Article  CAS  PubMed  Google Scholar 

  15. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer. 2006;106:208–13.

    Article  CAS  PubMed  Google Scholar 

  16. Rock MG, Pritchard DJ, Reiman HM, et al. Extra-abdominal desmoid tumors. J Bone Joint Surg Am. 1984;66:1369–74.

    Article  CAS  PubMed  Google Scholar 

  17. Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. Arch Surg. 1989;124:191–6.

    Article  CAS  PubMed  Google Scholar 

  18. Bonvalot S, Ternes N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.

    Article  PubMed  Google Scholar 

  19. Gaposchkin CG, Bilsky MH, Ginsberg R, et al. Function-sparing surgery for desmoid tumors and other low-grade fibrosarcomas involving the brachial plexus. Neurosurgery. 1998;42:1297–301; discussion 1301–3.

    Article  CAS  PubMed  Google Scholar 

  20. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg. 1999;229:866–72; discussion 872–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Pires de Camargo V, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116:2258–65.

    Google Scholar 

  22. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer. 1993;72:3244–7.

    Article  CAS  PubMed  Google Scholar 

  23. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol. 2006;24:11–2.

    Article  PubMed  Google Scholar 

  24. Fong Y, Rosen PP, Brennan MF. Multifocal desmoids. Surgery. 1993;114:902–6.

    CAS  PubMed  Google Scholar 

  25. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.

    Article  PubMed  Google Scholar 

  26. Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.

    Article  CAS  PubMed  Google Scholar 

  27. Colombo C, Miceli R, Le Pechoux C, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.

    Article  CAS  PubMed  Google Scholar 

  28. Gronchi A, Colombo C, Le Pechoux C, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25:578–83.

    Article  CAS  PubMed  Google Scholar 

  29. Tryphonopoulos P, Weppler D, Levi DM, et al. Transplantation for the treatment of intra-abdominal fibromatosis. Transplant Proc. 2005;37:1379–80.

    Article  CAS  PubMed  Google Scholar 

  30. Kasper B, Baumgarten C, Bonvalot S, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51:127–36.

    Article  CAS  PubMed  Google Scholar 

  31. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119:3696–702.

    Article  CAS  PubMed  Google Scholar 

  32. van Broekhoven DL, Verhoef C, Grunhagen DJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22:1464–70.

    Article  PubMed  Google Scholar 

  33. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441–7.

    Article  PubMed  Google Scholar 

  34. Bus PJ, Verspaget HW, van Krieken JH, et al. Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol. 1999;11:1179–83.

    Article  CAS  PubMed  Google Scholar 

  35. Kinzbrunner B, Ritter S, Domingo J, et al. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer. 1983;52:2201–4.

    Article  CAS  PubMed  Google Scholar 

  36. Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116:233–40.

    CAS  PubMed  Google Scholar 

  37. Bertagnolli MM, Morgan JA, Fletcher CD, et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008;44:2404–10.

    Article  PubMed  Google Scholar 

  38. Weiss AJ, Horowitz S, Lackman RD, et al. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 1999;22:193–5.

    Article  CAS  PubMed  Google Scholar 

  39. Meazza C, Casanova M, Trecate G, et al. Objective response to hydroxyurea in a patient with heavily pre-treated aggressive fibromatosis. Pediatr Blood Cancer. 2010;55:587–8.

    Article  PubMed  Google Scholar 

  40. Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182–6.

    Article  CAS  PubMed  Google Scholar 

  41. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785–91.

    Google Scholar 

  42. Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clin Cancer Res. 2010;16:4884–91.

    Article  CAS  PubMed  Google Scholar 

  43. de Camargo VP, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116:2258–65.

    PubMed  PubMed Central  Google Scholar 

  44. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–25.

    Article  CAS  PubMed  Google Scholar 

  45. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22:452–7.

    Article  CAS  PubMed  Google Scholar 

  46. Skubitz KM, Manivel JC, Clohisy DR, et al. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol. 2009;64:635–40.

    Article  CAS  PubMed  Google Scholar 

  47. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17:4082–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Messersmith WA, Shapiro GI, Cleary JM, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21:60–7.

    Article  CAS  PubMed  Google Scholar 

  49. Kummar S, Do KT, O’Sullivan Coyne GH, et al. Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. J Clin Oncol. 2015;33:10563.

    Google Scholar 

  50. Hosalkar HS, Fox EJ, Delaney T, et al. Desmoid tumors and current status of management. Orthop Clin North Am. 2006;37:53–63.

    Article  PubMed  Google Scholar 

  51. Seinfeld J, Kleinschmidt-Demasters BK, Tayal S, et al. Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status. J Neurosurg. 2006;104:749–56.

    Article  CAS  PubMed  Google Scholar 

  52. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29:3553–8.

    Article  PubMed  Google Scholar 

  53. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258:347–53.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158–67.

    CAS  PubMed  Google Scholar 

  55. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21:1390–7.

    Article  CAS  PubMed  Google Scholar 

  56. Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol. 2009;35:129–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Alektiar, K.M., Maki, R.G. (2016). Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis). In: Management of Soft Tissue Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-41906-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41906-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41904-6

  • Online ISBN: 978-3-319-41906-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics